Tandem Diabetes Care, Inc. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings
Tandem Diabetes Care, Inc. (TNDM) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings of -$147.00 thousand for the 12-month period ending 2022-12-31, per its 10-K filed 2023-02-22.
Discontinued › Income Statement › Other Income
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings · last filed 2023-02-22
- Tandem Diabetes Care, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2022-12-31 was -$44.00K, a 237.50% decline year-over-year.
- Tandem Diabetes Care, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2022-09-30 was -$12.00K, a 103.06% decline year-over-year.
- Tandem Diabetes Care, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2022-06-30 was -$57.00K, a 120.96% decline year-over-year.
- Tandem Diabetes Care, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2022-03-31 was -$34.00K, a 104.93% decline year-over-year.
- Tandem Diabetes Care, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for fiscal 2022 was -$147.00K, a 110.61% decline from fiscal 2021.
- Tandem Diabetes Care, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for fiscal 2021 was $1.39M, a 91.89% decline from fiscal 2020.
- Tandem Diabetes Care, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for fiscal 2020 was $17.09M.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 3 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 6 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 9 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 12 month |
|---|---|---|---|---|
| 2022-12-31 | -$44.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-22 | -$56.00K derived: sum of 2 quarters · filed 2023-02-22 | -$113.00K derived: sum of 3 quarters · filed 2023-02-22 | -$147.00K 10-K · filed 2023-02-22 |
| 2022-09-30 | -$12.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-02 | -$69.00K derived: sum of 2 quarters · filed 2022-11-02 | -$103.00K 10-Q · filed 2022-11-02 | -$71.00K derived: sum of 4 quarters · filed 2023-02-22 |
| 2022-06-30 | -$57.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-03 | -$91.00K 10-Q · filed 2022-08-03 | -$59.00K derived: sum of 3 quarters · filed 2023-02-22 | $333.00K derived: sum of 4 quarters · filed 2023-02-22 |
| 2022-03-31 | -$34.00K 10-Q · filed 2022-05-04 | -$2.00K derived: sum of 2 quarters · filed 2023-02-22 | $390.00K derived: sum of 3 quarters · filed 2023-02-22 | $662.00K derived: sum of 4 quarters · filed 2023-02-22 |
| 2021-12-31 | $32.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-22 | $424.00K derived: sum of 2 quarters · filed 2023-02-22 | $696.00K derived: sum of 3 quarters · filed 2023-02-22 | $1.39M 10-K · filed 2023-02-22 |
| 2021-09-30 | $392.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-02 | $664.00K derived: sum of 2 quarters · filed 2022-11-02 | $1.35M 10-Q · filed 2022-11-02 | -$1.47M derived: sum of 4 quarters · filed 2023-02-22 |
| 2021-06-30 | $272.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-03 | $962.00K 10-Q · filed 2022-08-03 | -$1.86M derived: sum of 3 quarters · filed 2023-02-22 | $1.79M derived: sum of 4 quarters · filed 2023-02-22 |
| 2021-03-31 | $690.00K 10-Q · filed 2022-05-04 | -$2.13M derived: sum of 2 quarters · filed 2023-02-22 | $1.52M derived: sum of 3 quarters · filed 2023-02-22 | |
| 2020-12-31 | -$2.82M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-22 | $829.00K derived: sum of 2 quarters · filed 2023-02-22 | $17.09M 10-K · filed 2023-02-22 | |
| 2020-09-30 | $3.65M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | $19.91M 10-Q · filed 2021-11-03 | ||
| 2020-06-30 | $16.26M 10-Q · filed 2021-08-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IRADIMED CORP (IRMD) | United States | $1.089B | 52.92 |
| PROCEPT BioRobotics Corp (PRCT) | United States | $1.001B | -11.77 |
| ARTIVION, INC. (AORT) | United States | $1.123B | -345.09 |
| Beta Bionics, Inc. (BBNX) | United States | $0.979B | -9.66 |
| SpyGlass Pharma, Inc. (SGP) | United States | $0.925B | |
| INTEGRA LIFESCIENCES HOLDINGS CORP (IART) | United States | $1.234B | -193.02 |
| SI-BONE, Inc. (SIBN) | United States | $0.830B | -49.82 |
| MIMEDX GROUP, INC. (MDXG) | United States | $0.687B | 89.92 |
| ANGIODYNAMICS INC (ANGO) | United States | $0.632B | -13.02 |
| ORTHOPEDIATRICS CORP (KIDS) | United States | $0.592B |